InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,570.64
(
-0.89%
)
US TECH 100
19,035.20
(
-1.37%
)
Dow Jones
40,712.78
(
-0.43%
)
Brent Oil
76.71
(
0.15%
)
Bitcoin
60,534.08
(
0.27%
)
Post# of 252959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120328
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 134686

Thursday, 04/19/2012 10:37:27 PM

Thursday, April 19, 2012 10:37:27 PM

Post# of 252959
Presidio provides update on its NS5A inhibitor, PPI-668:

http://finance.yahoo.com/news/presidio-pharmaceuticals-announces-phase-1a-040000825.html

PPI-668 is the successor to PPI-461, a drug that Presidio acquired from XTLB at a firesale price about four years ago (#msg-27791536).

p.s. If XTLB had waited until now to sell a preclinical NS5A inhibitor, they probably could have walked away with real money :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up